ETC
CRSP icon

Exchange Traded Concepts’s CRISPR Therapeutics CRSP Stock Holding History

Exchange Traded Concepts’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,555
Closed -$903K – 1465
2025
Q2 		$903K Buy
+18,555
New +$718K 0.01% 719
2025
Q1 		– Sell
-16,127
Closed -$635K – 1292
2024
Q4 		$635K Sell
16,127
-3,065
-16% -$145K 0.01% 747
2024
Q3 		$902K Buy
19,192
+3,563
+23% +$181K 0.02% 556
2024
Q2 		$844K Buy
15,629
+3,650
+30% +$211K 0.02% 496
2024
Q1 		$816K Buy
+11,979
New +$858K 0.02% 488
2023
Q2 		– Sell
-22,185
Closed -$1M – 1325
2023
Q1 		$1M Buy
+22,185
New +$1.08M 0.03% 329
2021
Q2 		– Sell
-342
Closed -$42K – 1130
2021
Q1 		$42K Buy
342
+39
+13% +$5.89K ﹤0.01% 825
2020
Q4 		$46K Sell
303
-5,285
-95% -$625K ﹤0.01% 746
2020
Q3 		$467K Buy
5,588
+1,477
+36% +$131K 0.03% 317
2020
Q2 		$302K Buy
4,111
+1,963
+91% +$115K 0.05% 372
2020
Q1 		$91K Buy
2,148
+1,254
+140% +$64.7K 0.05% 266
2019
Q4 		$54K Buy
+894
New +$48.8K 0.01% 274

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Exchange Traded Concepts's CRSP Position: Q3 2025 in Review

Exchange Traded Concepts sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 18,555 shares — an estimated $903K sold.

Exchange Traded Concepts first reported a position in CRSP in Q4 2019 and held it in 12 quarters. The position peaked at $1M in Q1 2023. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

  • Exchange Traded Concepts reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 18,555 CRISPR Therapeutics shares in Q3 2025, an estimated $903K.
  • Exchange Traded Concepts first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 12 quarters.
  • Exchange Traded Concepts's CRISPR Therapeutics position peaked at $1M in Q1 2023.
  • 440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Exchange Traded Concepts's 13F filing for Q3 2025, filed 14 Oct 2025.